Evaluation of pseudoprogression in patients with glioblastoma multiforme using dynamic magnetic resonance imaging with ferumoxytol calls RANO criteria into question

• Published in: Neuro-oncology (Charlottesville, Va.) Va.), 2014-08, Vol.16 (8), p.1146-1154
• Main Authors: Nasseri, Morad, Gahramanov, Seymur, Netto, Joao Prola, Fu, Rongwei, Muldoon, Leslie L, Varallyay, Csanad, Hamilton, Bronwyn E, Neuwelt, Edward A
• Format: Article
• Language: English
• Subjects: Adult; Aged; Aged, 80 and over; Brain Neoplasms - diagnosis; Brain Neoplasms - pathology; Brain Neoplasms - therapy; Chemoradiotherapy - methods; Combined Modality Therapy - methods; Disease Progression; Female; Ferrosoferric Oxide - therapeutic use; Glioblastoma - diagnosis; Glioblastoma - pathology; Glioblastoma - therapy; Humans; Magnetic Resonance Imaging - methods; Male; Middle Aged; Neuroimaging; Treatment Outcome; Young Adult
• ISSN: 1522-8517; 1523-5866
• DOI: 10.1093/neuonc/not328

Diagnosis of pseudoprogression in patients with glioblastoma multiforme (GBM) is limited by Response Assessment in Neuro-Oncology (RANO) criteria to 3 months after chemoradiotherapy (CRT). Frequency of pseudoprogression occurring beyond this time limit was determined. Survival comparison was made between pseudoprogression and true progression patients as determined by using perfusion magnetic resonance imaging with ferumoxytol (p-MRI-Fe). Fifty-six patients with GBM who demonstrated conventional findings concerning for progression of disease post CRT were enrolled in institutional review board-approved MRI protocols. Dynamic susceptibility-weighted contrast-enhanced p-MRI-Fe was used to distinguish true progression from pseudoprogression using relative cerebral blood volume (rCBV) values. rCBV of 1.75 was assigned as the cutoff value. Participants were followed up using RANO criteria, and survival data were analyzed. Twenty-seven participants (48.2%) experienced pseudoprogression. Pseudoprogression occurred later than 3 months post CRT in 8 (29.6%) of these 27 participants (ie, 8 [14.3%] of the 56 patients meeting the inclusion criteria). Overall survival was significantly longer in participants with pseudoprogression (35.2 months) compared with those who never experienced pseudoprogression (14.3 months; P < .001). Pseudoprogression presented after 3 months post CRT in a considerable portion of patients with GBM, which raises doubts about the value of the 3-month time limit of the RANO criteria. Accurate rCBV measurement (eg, p-MRI-Fe) is suggested when there are radiographical concerns about progression of disease in GBM patients, regardless of any time limit. Pseudoprogression correlates with significantly better survival outcomes.